What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of busulfan plus low dose melphalan versus high dose melphalan for autologous stem cell transplantation in multiple myeloma.

March 22, 2026Expert Review of Hematology

Efficacy and safety profile of busulfan plus low dose melphalan (BUMEL) versus high dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cells transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

SMShahzaib MaqboolRawalpindi Medical University IKImran KhanWoodhull Medical and Mental Health Center MIMuhammad IbrahimRawalpindi Medical University

Discussion

Member takes

Implication

A systematic review compares busulfan plus low dose melphalan and high dose melphalan in multiple myeloma, suggesting individualized treatment options.

Key Points

This research aims to evaluate the efficacy and safety of busulfan plus low dose melphalan versus high dose melphalan for autologous stem cell transplantation in multiple myeloma.
Conducted a systematic review and meta-analysis of existing studies.
Compared outcomes of BUMEL with MEL200 conditioning regimens.
Analyzed disease control and toxicity levels.
BUMEL showed improved disease control compared to MEL200.
Increased toxicity was noted with the BUMEL regimen.
No clear advantage in overall survival was identified between the two regimens.

Cite This Study

Maqbool et al. (2026) studied this question.

synapsesocial.com/papers/69bf8692f665edcd009e8f44 https://doi.org/10.1080/17474086.2026.2649831

View Full Paper

Ask AI

Bookmark

Implication

A systematic review compares busulfan plus low dose melphalan and high dose melphalan in multiple myeloma, suggesting individualized treatment options.

Efficacy and safety profile of busulfan plus low dose melphalan (BUMEL) versus high dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cells transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and safety profile of busulfan plus low dose melphalan (BUMEL) versus high dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cells transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider